This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
Sepsis	Not applicable	<p>Studies in mice suggest that the bioactive lipid resolvin D2 (RvD2) could help reduce sepsis-related inflammation. In mouse models of microbial sepsis, treatment with RvD2 reduced both infiltration of leukocytes into the peritoneum and levels of proinflammatory cytokines, increased clearance of bacteria from the peritoneum and blood and improved survival compared with no treatment. Next steps could include identifying RvD2 analogs with more potent anti-inflammatory effects than RvD2.</p> <p>Xigris drotrecogin alfa, a recombinant human activated protein C (APC) from Eli Lilly and Co., is marketed to treat sepsis.</p> <p>Eisai Co. Ltd.'s eritoran (E5564), a synthetic lipid targeting toll-like receptor 4 (TLR4), is in Phase III testing to treat severe sepsis.</p> <p>Biosynexus Inc. antistaphylococcal antibody pagibaximab (formerly BSYX-A110) is in Phase II/III testing to prevent staphylococcal sepsis in newborns of very low birth weight.</p> <p>Agennix Inc.'s talactoferrin alfa, a recombinant human lactoferrin (rhLF) immunomodulatory protein, is in Phase II testing to treat sepsis.</p> <p>SciBX 2(43); doi:10.1038/scibx.2009.1605 Published online Nov. 5, 2009</p>	Patent and licensing status unavailable	<p>Spite, M. <i>et al. Nature</i>; published online Oct. 28, 2009; doi:10.1038/nature08541</p> <p>Contact: Charles Serhan, Harvard Medical School, Boston, Mass. e-mail: cnserhan@zeus.bwh.harvard.edu</p>